Cresset Asset Management LLC Grows Stock Position in HCA Healthcare, Inc. $HCA

Cresset Asset Management LLC boosted its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 83.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 2,716 shares of the company’s stock after buying an additional 1,239 shares during the quarter. Cresset Asset Management LLC’s holdings in HCA Healthcare were worth $1,041,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Saudi Central Bank acquired a new position in HCA Healthcare in the first quarter valued at about $26,000. WPG Advisers LLC acquired a new position in shares of HCA Healthcare in the 1st quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new stake in HCA Healthcare in the 2nd quarter valued at approximately $27,000. Chung Wu Investment Group LLC acquired a new position in HCA Healthcare during the second quarter worth $27,000. Finally, Clearstead Trust LLC raised its holdings in shares of HCA Healthcare by 311.8% in the 2nd quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock valued at $27,000 after buying an additional 53 shares during the period. 62.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

HCA Healthcare Stock Down 3.9%

Shares of HCA opened at $469.50 on Thursday. The company has a market capitalization of $107.14 billion, a price-to-earnings ratio of 18.15, a price-to-earnings-growth ratio of 1.44 and a beta of 1.36. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $520.00. The stock has a 50 day moving average price of $463.37 and a 200 day moving average price of $412.38.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The firm had revenue of $19.16 billion for the quarter, compared to the consensus estimate of $18.55 billion. During the same period last year, the firm posted $4.90 EPS. The company’s revenue was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, equities analysts anticipate that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be given a $0.72 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.6%. HCA Healthcare’s dividend payout ratio is 11.13%.

Analyst Ratings Changes

HCA has been the topic of a number of recent research reports. Mizuho boosted their price target on shares of HCA Healthcare from $475.00 to $505.00 and gave the stock an “outperform” rating in a research note on Monday, October 27th. The Goldman Sachs Group increased their target price on shares of HCA Healthcare from $470.00 to $520.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research report on Monday, October 27th. Weiss Ratings reissued a “buy (b)” rating on shares of HCA Healthcare in a research note on Monday. Finally, Barclays lifted their price objective on HCA Healthcare from $445.00 to $494.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $474.53.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.